Welcome to our dedicated page for AVAI BIO SEC filings (Ticker: AVAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Avant Technologies Inc. (OTCQB: AVAI) provide formal detail on the company’s material agreements, corporate actions, and governance decisions. For this issuer, recent Forms 8-K are particularly important because they document the structure and terms of key joint ventures and licensing arrangements that define its biotech and healthcare strategy.
Among the notable disclosures is a Form 8-K describing a Joint Venture and License Agreement with SGAustria Pte. Ltd. to form Insulinova, Inc. The filing outlines that Insulinova will be owned 50% by Avant and 50% by SGAustria, and that Avant has agreed to contribute resources and capital for Insulinova’s formation and initial operations in exchange for common stock. Another 8-K details a similar 50/50 Joint Venture and License Agreement with SGAustria/Austrianova to establish Klothonova Inc., which is focused on encapsulated Klotho-producing cell therapies.
Avant’s SEC filings also include an 8-K reporting that the company filed an application with FINRA to change its corporate name from Avant Technologies Inc. to Avaí Bio, Inc., with the AVAI ticker symbol remaining in place until the corporate action is declared effective and any new symbol is assigned. These filings help clarify how Avant is reshaping its corporate identity around biotechnology and longevity-focused programs.
On this page, investors can review Avant’s 8-K reports and other SEC documents as they become available through EDGAR. Stock Titan’s tools can surface new filings in real time and provide AI-powered summaries that explain the key terms of joint venture agreements, ownership structures, and capital commitments. Users can quickly see how each filing relates to Avant’s broader strategy in cell-based therapies, Klotho programs, and AI-enabled healthcare, without having to read every line of the underlying documents.
Avaí Bio, Inc. reported another loss-making quarter with no revenue and a larger deficit. For the three months ended December 31, 2025, the company recorded a net loss of $553,727, bringing the nine‑month loss to $1,494,332.
As of December 31, 2025, Avaí Bio had total assets of $172,912, versus total liabilities of $2,967,398, resulting in a stockholders’ deficit of $2,794,486. Cash and cash equivalents were just $50,402, while accounts payable and various loans and convertible notes made up a heavy current liability load.
The company’s auditors highlight substantial doubt about its ability to continue as a going concern, citing recurring losses and the absence of a stable revenue base. Management plans to rely on additional investment capital while pursuing AI and biotech joint ventures that may require up to tens of millions of dollars in future funding commitments.
AVAI Bio, Inc., formerly Avant Technologies, Inc., reported a corporate name change. On February 3, 2026, the Nevada corporation filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name to Avaí Bio, Inc. The company’s ticker symbol will remain “AVAI.”
Avaí Bio, Inc. (formerly Avant Technologies Inc.) filed its quarterly report for the period ended September 30, 2025. The company reported $0 revenue and a net loss of $453,016 for the quarter. For the six months, net loss was $940,605 as operating expenses focused on G&A, marketing, and initial R&D.
Liquidity remains tight: cash was $91,995 and total assets were $231,372, against total liabilities of $2,532,131, resulting in a stockholders’ deficit of $2,300,759. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Operating cash use for the six months was $611,890, largely offset by $622,832 from financing activities, including related party loans and promissory notes carrying default interest terms.
The company outlined two joint ventures: with Ainnova Tech Inc. (commitment up to $20,000,000 over 12 months) and with Austrianova (up to $1.5 million over 18 months), each at 50/50 ownership. It terminated a prior equity line and withdrew a related S-1, and is pursuing revised financing structures. Common shares outstanding were 137,829,465 at quarter-end and 138,031,533 as of November 14, 2025.
Avant Technologies Inc. (AVAI) entered a Joint Venture and License Agreement with SGAustria Pte. Ltd. to form Insulinova, Inc. Effective November 1, 2025, the parties will co-own Insulinova on a 50%/50% basis and operate it under a limited liability company agreement.
Austrianova intends to contribute its proprietary cell encapsulation intellectual property, know-how, and related resources. AVAI will contribute all resources and capital required for the first eighteen months, not to exceed $1.5 million USD, in exchange for Insulinova common stock, and will use its best efforts to help arrange additional funding at no cost to Austrianova. The full agreement is attached as Exhibit 10.1.
Avant Technologies Inc. entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd. (Austrianova) to form a new company, Klothonova Inc. Avant will provide all resources and capital needed for Klothonova’s formation and operations for the next 18 months, up to
Austrianova, a biotech company specializing in cell biology and proprietary cell encapsulation technology, will contribute its intellectual property, know-how, and resources. Ownership of Klothonova will be split 50% to Avant and 50% to Austrianova, and it will be governed under a limited liability company agreement. The full Joint Venture and License Agreement is attached as Exhibit 10.1.
Avant Technologies Inc. reported that it has filed an application with FINRA to change its corporate name. The company plans to change its name from Avant Technologies Inc. to Avaí Bio, Inc. to better reflect its current business. The ticker symbol will remain “AVAI” until FINRA declares the corporate action effective and, if applicable, assigns a new trading symbol.
FAQ
What is the current stock price of AVAI BIO (AVAI)?
What is the market cap of AVAI BIO (AVAI)?
